X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the terms of the license agreement TB Alliance obtains the exclusive worldwide license to develop and commercialize Q203 (telacebec), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis and some NTM infections.
Lead Product(s): Telacebec
Therapeutic Area: Infections and Infectious Diseases Product Name: Q203
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qurient
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 03, 2023
Details:
Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis regardless of drug resistance status.
Lead Product(s): Telacebec
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
